Share:
ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / May 4, 2021 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, announced today its interim management statement for the period ending March 31, 2021. Molecular Partners continues to grow and expand the reach of our DARPin® therapeutics platform, with the COVID-19 pandemic forming a meaningful change agent for us, said Patrick Amstutz, Ph.D., chief executive officer of Molecular Partners. Twelve months ago, we were only at the initiating stages of our COVID-19 program, while this year we are approaching Phase 3 clinical trials with our partners at Novartis. I am extremely proud of our team and partners for not only bringing us to this stage of development in our new antiviral program, but also for continuing to advance our targeted oncology pipeline.
(1)
ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / May 4, 2021 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, announced today its interim management statement for the period ending March 31, 2021. Molecular Partners continues to grow and expand the reach of our DARPin® therapeutics platform, with the COVID-19 pandemic forming a meaningful change agent for us, said Patrick Amstutz, Ph.D., chief executive officer of Molecular Partners. Twelve months ago, we were only at the initiating stages of our COVID-19 program, while this year we are approaching Phase 3 clinical trials with our partners at Novartis. I am extremely proud of our team and partners for not only bringing us to this stage of development in our new antiviral program, but also for continuing to advance our targeted oncology pipeline.
Interim Management Statement Q1 2021: Major Advances in COVID-19 Program, Continued Progress in Oncology Pipeline pittsburghstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pittsburghstar.com Daily Mail and Mail on Sunday newspapers.
J. Scott Applewhite | AP Photos
As an editorial board, we have long believed that if any group deserves a second chance to make good after committing even the worst of crimes, it’s teenagers.
Granting a second chance at redemption to an impressionable, impulsive 15-year-old whose crime came maybe after years of abuse or living amid violence and poverty, is the decent thing to do. And it’s a view supported by the science of adolescent brain development, which has found through ample research that our brains are not fully developed able to rein in rash behavior, make rational decisions and weigh the long-term consequences of actions until our mid-20s.
Molecular Partners Files Registration Statement for Proposed Initial Public Offering in the United States theusnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theusnews.com Daily Mail and Mail on Sunday newspapers.